Skip to main content

Shareholder Protection Insurance Cover

WATTS NEWS

BLOG: Can I find life insurance for clients taking weight loss injections?

Posted November 13, 2026

History.

GLP-1 (Glucagon-like peptide-1) is a hormone produced in the small intestine, generally after eating a meal. Its release triggers a complex cascade of biological processes, including signalling to the pancreas to release insulin (helping cells to absorb glucose), slowing the rate at which the stomach empties, and also reducing appetite via signalling to the brain.

This hormone was initially looked at very closely as a potential medication source for type 2 diabetes, but the issue that science needed to solve was the very short life span of the GLP-1s, measures in less than two minutes before it is broken down by an enzyme DPP-4.

The Gila Monster and GLP-1s.

Interestingly, the solution to this conundrum originated from the venomous saliva of the Gila monster- a large lizard indigenous to South West US/Mexico, and a chemical compound found within it, called exendin-4 discovered in 1995.

Drs John Eng and Jean-Pierre Raufman found this compound to be very similar to human GLP-1 but, being naturally resistant to enzymatic breakdown, much longer lasting. They licensed this discovery to a pharmaceutical company, and in 2005 the drug exenatide (marketed as Byetta) was licensed by the FDA for medical use towards the control of type 2 diabetes.

It was observed over time that, on average, the early recipients of this medication were losing 15% of their body weight, and the wider physiological (and fiscal) benefits drove further innovations, culminating in the first semaglutide medications- Ozempic and Wegovy. Mounjaro- released in 2022- is one of the most developed versions of this medication journey, stimulating both GLP-1 and GIP receptors. This dual action approach has far increased the impact these medications have upon weight loss, and a $75BN USD market was born.

Metabolic health

With a current average weight loss of over 20%, improvement in heart health, reduction in the progression of chronic kidney disease, lowering of HbA1c levels, reduction of liver fat and a myriad of other health benefits, the impact upon public medicine and the healthy life span of a population is clear, but the economic case towards funding is far from resolved.

In the UK, the NHS has specific criteria towards meeting the cost of GLP-1 medication, currently limited to patients with a BMI of 35+ with 4 out of the 5 of the below criteria:

Type 2 diabetes, high blood pressure, high cholesterol, cardiovascular disease, or obstructive sleep apnoea

The future of these medications

The future market of GLP-1 medications is expected to expand greatly into preventative chronic disease management- beyond obesity and diabetes- towards cardiovascular disease management/prevention.

Mounting evidence even indicates help with addiction behaviours such as smoking, alcohol use disorders and gambling, with 15 clinical trials in progress globally. By the targeting of brain reward pathways GLP-1s have the scope to open up entirely new treatment options in these difficult to treat, often chronic conditions.

Insurance and the underwriting of GLP-1s

With these medications becoming mainstream relatively recently, there have been quick changes to underwriting stances at major insurers as the volume of applications disclosing this has increased. I spoke with Craig Paterson, Chief Underwriter at Royal London, who said:

‘We want to support customers who are taking positive steps to improve their health. Where weight loss is sustained and well managed, this can often lead to improved underwriting terms. At the same time, we need to understand whether treatment has been appropriately prescribed and medically supervised, while also considering the short-term risk of weight being regained if medication is stopped’.

Case Study.

Gabriella is a female, age 40, who took Mounjaro for a 12-month period, prescribed via an online pharmacy and paid for privately. She came to us for advice around personal protection. Her height is 5 foot 4 and her weight during the period on medication reduced from 97Kg (BMI 37) to 77Kg (BMI 29). She stopped taking the medication two months ago and has maintained the same weight since.

We spoke with several insurers* to gauge their appetite for provide cover for life insurance, critical illness and income protection, and received the following responses:

InsurerLife InsuranceCritical IllnessIncome Protection
Legal and General  Standard termsStandard termsStandard terms
Liverpool Victoria  +25% increase+25% increase+25% increase
Aviva  +50% increase+50% increase+50% increase
Scottish Widows  Standard termsStandard termsStandard terms
Royal London  +25% increase+50% increase+25% increase
British Friendly  Not ApplicableNot Applicable+25% increase

The variance between insurers is quite sharp, and shows the real value that a specialist broker can add in placing the correct cover with the best fitting insurer. The primary caution from insurers, now that their initial concerns over the medication itself have largely dissipated, is the long term sustainability of the weight loss. Some of the insurers operate an ‘add back’ system, adding back 50% of the weight lost, and calculating the premium based upon the BMI that this would generate. Most remove this pre-caution after 12 months’ cessation of medication.

What we always know as advisers is that, as the data changes, and as claims statistics grow, the underwriting guides and manuals will change accordingly. Keeping abreast of this is imperative to be able to give the very highest quality advice to clients.

For more information contact our Director and Head of Financial Planning, Barry Jones, on 01270 620 555

*responses/underwriting stances correct as of Sept 2026.

This article has been published by Moneyfacts.

Note that life insurance plans typically have no in cash value at any time and cover will cease at the end of term.If premiums stop then the cover will lapse. Cover is subject to terms and conditions and may have exclusions. Definitions of illnesses vary from product provider and will be explained within the policy documentation.